pancrelipase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5161	53608-75-6

Description:

Molecule	Description
Synonyms: pancrelipase pancreatin pancreatic extract pancrelipase	A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

pancrelipase
pancreatin
pancreatic extract pancrelipase

A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angina bullosa haemorrhagica	66.12	16.69	12	6280	132	50598700
Needle issue	55.63	16.69	24	6268	7251	50591581
Muscle swelling	54.20	16.69	12	6280	378	50598454
Facial asymmetry	47.81	16.69	12	6280	654	50598178
Vulval disorder	47.05	16.69	12	6280	698	50598134
Early satiety	46.05	16.69	12	6280	760	50598072
Frequent bowel movements	38.27	16.69	23	6269	13895	50584937
Breast pain	33.21	16.69	17	6275	7527	50591305
Infective pulmonary exacerbation of cystic fibrosis	32.45	16.69	17	6275	7892	50590940
Infectious thyroiditis	32.34	16.69	5	6287	18	50598814
Fracture blisters	31.99	16.69	6	6286	80	50598752
Liver abscess	31.74	16.69	12	6280	2581	50596251
Abdominal distension	28.52	16.69	40	6252	72863	50525969
Body temperature decreased	27.74	16.69	20	6272	16375	50582457
Pancreatic carcinoma	27.35	16.69	14	6278	6200	50592632
Drug ineffective	26.73	16.69	38	6254	819295	49779537
Dehydration	25.94	16.69	58	6234	152391	50446441
Pancreatic carcinoma recurrent	25.93	16.69	5	6287	78	50598754
Pancreatolithiasis	25.54	16.69	6	6286	247	50598585
Localised oedema	24.46	16.69	12	6280	4855	50593977
Pallor	23.60	16.69	21	6271	23178	50575654
Pyrexia	23.18	16.69	101	6191	380102	50218730
Biliary sepsis	22.46	16.69	7	6285	843	50597989
Intestinal dilatation	22.43	16.69	8	6284	1460	50597372
Eosinophilic pneumonia chronic	22.21	16.69	5	6287	170	50598662
Crepitations	21.69	16.69	12	6280	6207	50592625
Derailment	21.28	16.69	4	6288	54	50598778
Rales	21.18	16.69	14	6278	9964	50588868
Weight decreased	21.18	16.69	68	6224	221177	50377655
Flatulence	21.13	16.69	22	6270	29436	50569396
Subileus	20.75	16.69	9	6283	2750	50596082
General physical health deterioration	20.74	16.69	51	6241	142383	50456449
Cystic fibrosis	20.43	16.69	9	6283	2855	50595977
Underdose	19.92	16.69	18	6274	20260	50578572
Blood pressure diastolic increased	19.68	16.69	12	6280	7431	50591401
Mass	18.69	16.69	14	6278	12143	50586689
Pancreatitis	17.58	16.69	24	6268	42590	50556242
Blood magnesium decreased	17.48	16.69	13	6279	11147	50587685
Faeces discoloured	17.21	16.69	15	6277	16109	50582723
Haemorrhoids	16.95	16.69	16	6276	19037	50579795

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	65.82	16.25	29	5425	6207	29562866
General physical health deterioration	57.38	16.25	82	5372	102775	29466298
Pancreatic carcinoma	49.93	16.25	25	5429	7125	29561948
Toxic optic neuropathy	37.42	16.25	11	5443	730	29568343
Pancreatic carcinoma metastatic	36.49	16.25	15	5439	2706	29566367
Abdominal pain upper	35.98	16.25	50	5404	60943	29508130
Diarrhoea	33.32	16.25	135	5319	332563	29236510
Needle issue	25.88	16.25	14	5440	4669	29564404
Enterocolitis infectious	23.95	16.25	9	5445	1280	29567793
Pancreatic neoplasm	23.71	16.25	8	5446	833	29568240
Hypertransaminasaemia	23.39	16.25	12	5442	3594	29565479
Hepatic infection	23.13	16.25	7	5447	513	29568560
Cholangitis	22.09	16.25	15	5439	7522	29561551
Adjustment disorder with depressed mood	22.04	16.25	6	5448	301	29568772
Liver abscess	21.34	16.25	11	5443	3327	29565746
Product residue present	21.09	16.25	10	5444	2529	29566544
Pancreatic failure	20.98	16.25	7	5447	704	29568369
Hypopnoea	20.59	16.25	8	5446	1246	29567827
Abdominal pain	20.42	16.25	63	5391	135294	29433779
Blood pressure systolic increased	20.38	16.25	20	5434	16825	29552248
Biliary tract infection	19.24	16.25	6	5448	486	29568587
Pancreatic disorder	18.98	16.25	8	5446	1535	29567538
Hydrocholecystis	17.63	16.25	5	5449	292	29568781
Body temperature decreased	17.46	16.25	15	5439	10649	29558424
Steatorrhoea	17.22	16.25	6	5448	688	29568385
Abdominal lymphadenopathy	17.17	16.25	6	5448	694	29568379
Malignant neoplasm progression	16.78	16.25	40	5414	73819	29495254
Intestinal obstruction	16.42	16.25	19	5435	19258	29549815

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatic carcinoma	82.74	14.34	39	11178	10334	64477181
Infective pulmonary exacerbation of cystic fibrosis	80.93	14.34	40	11177	11756	64475759
Needle issue	77.47	14.34	36	11181	9236	64478279
General physical health deterioration	71.91	14.34	128	11089	204297	64283218
Pancreatic carcinoma metastatic	50.59	14.34	20	11197	3458	64484057
Angina bullosa haemorrhagica	46.36	14.34	10	11207	196	64487319
Liver abscess	42.56	14.34	20	11197	5260	64482255
Toxic optic neuropathy	39.63	14.34	12	11205	935	64486580
Abdominal pain upper	39.26	14.34	91	11126	174939	64312576
Muscle swelling	38.21	14.34	11	11206	719	64486796
Diarrhoea	37.66	14.34	234	10983	722470	63765045
Vulval disorder	37.56	14.34	10	11207	489	64487026
Body temperature decreased	37.23	14.34	33	11184	25895	64461620
Drug ineffective	34.88	14.34	58	11159	840189	63647326
Pancreatic failure	34.53	14.34	12	11205	1448	64486067
Facial asymmetry	34.23	14.34	10	11207	689	64486826
Abdominal distension	33.54	14.34	60	11157	95934	64391581
Biliary sepsis	30.95	14.34	11	11206	1417	64486098
Fracture blisters	29.98	14.34	6	11211	80	64487435
Early satiety	29.42	14.34	10	11207	1129	64486386
Pancreatic carcinoma recurrent	28.35	14.34	6	11211	107	64487408
Pancreatic neoplasm	27.44	14.34	10	11207	1385	64486130
Biliary tract infection	27.14	14.34	9	11208	942	64486573
Pancreatolithiasis	27.08	14.34	7	11210	305	64487210
Toxicity to various agents	26.75	14.34	15	11202	363498	64124017
Weight decreased	26.47	14.34	109	11108	285630	64201885
Bile duct stone	25.84	14.34	14	11203	4964	64482551
Frequent bowel movements	25.68	14.34	23	11194	18282	64469233
Cholangitis	24.57	14.34	18	11199	10784	64476731
Malignant neoplasm progression	23.46	14.34	57	11160	112814	64374701
Pancreatic disorder	23.22	14.34	11	11206	2943	64484572
Infectious thyroiditis	22.21	14.34	5	11212	120	64487395
Enterocolitis infectious	21.93	14.34	10	11207	2454	64485061
Cystic fibrosis	21.65	14.34	11	11206	3423	64484092
Breast pain	21.31	14.34	14	11203	7047	64480468
Hepatic infection	20.13	14.34	7	11210	846	64486669
Abdominal pain	19.98	14.34	107	11110	312268	64175247
Pyrexia	19.75	14.34	165	11052	558479	63929036
Inappropriate schedule of product administration	19.59	14.34	47	11170	92239	64395276
Odynophagia	19.55	14.34	15	11202	9626	64477889
Product residue present	19.32	14.34	10	11207	3232	64484283
Derailment	18.86	14.34	4	11213	72	64487443
Pallor	18.62	14.34	28	11189	38753	64448762
Subileus	17.84	14.34	11	11206	4966	64482549
Rash morbilliform	17.51	14.34	11	11206	5130	64482385
Flatulence	17.48	14.34	26	11191	35640	64451875
Pancreatic pseudocyst	17.36	14.34	7	11210	1274	64486241
Hydrocholecystis	17.08	14.34	5	11212	347	64487168
Eosinophilic pneumonia chronic	16.90	14.34	5	11212	360	64487155
Product use issue	16.89	14.34	3	11214	151712	64335803
Steatorrhoea	16.83	14.34	6	11211	780	64486735
Chills	16.53	14.34	57	11160	137207	64350308
Intestinal dilatation	16.49	14.34	8	11209	2256	64485259
Decreased appetite	16.40	14.34	94	11123	281195	64206320
Hypertransaminasaemia	16.39	14.34	12	11205	7179	64480336
Dehydration	15.76	14.34	77	11140	216686	64270829
Rales	15.43	14.34	16	11201	15213	64472302
Intercepted product storage error	15.30	14.34	4	11213	182	64487333
Idiopathic pulmonary fibrosis	15.17	14.34	9	11208	3791	64483724
Blood pressure systolic increased	14.87	14.34	29	11188	49424	64438091
Intestinal obstruction	14.39	14.34	24	11193	36262	64451253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D005765	Gastrointestinal Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Exocrine pancreatic insufficiency	indication	47367009	DOID:13316

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
FQ3DRG0N5K	UNII
4018109	VANDF
4018414	VANDF
C0770343	UMLSCUI
CHEMBL2108074	ChEMBL_ID
8519	PUBCHEM_CID
DB00085	DRUGBANK_ID
CHEMBL2108073	ChEMBL_ID
D020799	MESH_DESCRIPTOR_UI
235379	RXNORM
41216	MMSL
5227	MMSL
5615	MMSL
d01002	MMSL
d01003	MMSL
12236006	SNOMEDCT_US
387049005	SNOMEDCT_US
387265002	SNOMEDCT_US
48647005	SNOMEDCT_US
D010194	MESH_DESCRIPTOR_UI
001234	NDDF
001235	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FESTAL PLUS	HUMAN OTC DRUG LABEL	3	72689-0010	TABLET	315 mg	ORAL	unapproved drug other	6 sections
Stozyme	HUMAN OTC DRUG LABEL	4	72850-0004	TABLET	36.46 1	ORAL	unapproved drug other	7 sections